


CLAIMS

1. A compound according to general formula (I)



wherein

A represents C₆-cycloalkyl, wherein said C₆-cycloalkyl is optionally substituted with one or more deuterium;

R₁ represents C₁-alkyl, wherein said C₁-alkyl is optionally substituted with one or more deuterium;

R₂ represents C₁-alkyl, wherein said C₁-alkyl is substituted with a substituent selected from R₆; and wherein said C₁-alkyl is optionally substituted with one or more deuterium;

R₃ represents C₂-alkyl, wherein said C₂-alkyl is substituted with a substituent selected from R₇ and wherein said C₂-alkyl is optionally substituted with one or more deuterium;

R₄ represents hydrogen or deuterium;


R₅ represents hydrogen or deuterium;

R₆ represents cyano;

R₇ represents hydroxy I;

or pharmaceutically acceptable salts, hydrates or solvates thereof.


2. The compound according to claim 1 wherein formula (I) is general formula (Ia)



da)

Wherein R₁-R₂, R₄-R₇ are as defined in claim 1 and wherein Ra, Rb, Rc and Rd each independently are selected from hydrogen and deuterium.

3. The compound according to claim 1 or 2 wherein formula (I) is general formula (Ib)



(Ib)

Wherein R₁-R₂, R₄-R₇, Ra, Rb, Rc and Rd are as defined in claim 1 or 2.

4. The compound according to any one of claims 1-3 selected from

trans-2-[4-[2-[1-Hydroxyethyl]-6-(methylamino)imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile,

trans-2-[4-[2-[(1S)-1-Hydroxyethyl]-6-(methylamino)imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile,

trans-2-[4-[2-[(1R)-1-Hydroxyethyl]-6-(methylamino)imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile,

trans-2-[4-[2-[1R)-1-Hydroxyethyl]-6-(trideuteriomethylamino)imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile,

trans-2-[4-[2-[1,2,2,2-Tetradeuterio-1-hydroxyethyl]-6-(methylamino)imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile,

cis-2-[4-[2-[1-Hydroxyethyl]-6-(methylamino)imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile and

cis-2-[4-[2-[(1R)-1-Hydroxyethyl]-6-(methylamino)imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile,

or pharmaceutically acceptable salts, hydrates or solvates thereof.

5. The compound according to any one of claims 1-4, wherein said compound is

trans-2-[4-[2-[(1R)-1-Hydroxyethyl]-6-(methylamino)imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile,

or pharmaceutically acceptable salts thereof.

6. A compound according to any one of claims 1-5 for use as a medicament.

7. The compound for use according to claim 6 in the prophylaxis and/or treatment of atopic dermatitis.

8. A pharmaceutical composition comprising a compound according to any one of claims 1-5 together with a pharmaceutically acceptable vehicle or excipient or pharmaceutically acceptable carrier(s).

9. The pharmaceutical composition according to claim 9 together with one or more other therapeutically active compound(s).

10. The compound according to any one of claims 1-5 for use in the treatment of a disease, which disease is responsive to the inhibition of JAK1 kinase activity.

11. A compound selected from

2-[trans-4-[(5-Amino-2-chloropyridin-4-yl)amino]cyclohexyl]acetonitrile

or salts thereof.

12. A compound selected from

2-[trans-4-[6-Chloro-2-(1-hydroxyethyl)-1H-imidazo[4,5-c]pyridin-1-yl]cyclohexyl]-acetonitrile,

2-[trans-4-[6-Chloro-2-[(1R)-1-hydroxyethyl]-1H-imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile and

trans-2-[4-[6-Chloro-2-(1,2,2,2-tetradeuterio-1-hydroxy-ethyl)imidazo[4,5-c]pyridin-1-yl]cyclohexyl]acetonitrile,

or salts thereof.